"The NADINA trial aims to compare the efficacy of neoadjuvant ipilimumab plus nivolumab with that of adjuvant nivolumab in macroscopic stage III melanoma. Patients diagnosed with recurrent or de novo stage III melanoma, including up to three in-transit metastases, will be randomly assigned to receive neoadjuvant treatment or adjuvant treatment."
#Immunology #Immunotherapy

https://www.nature.com/articles/s41591-023-02699-5#:~:text=Nature%20Medicine%20asks%20leading%20researchers,lung%20cancer%20and%20patient%20triage